Hopper Jonathan Mark, Chief Medical Officer, has demonstrated a clear bias toward selling shares in Vericel Corporation (VCEL) over the past several years, as evidenced by SEC Form 4 filings. Since his first reported transaction in March 2025, Mark has executed 37 trades, all involving VCEL, with a total sell value of $1,858,959.57 and a total buy value of $499,236. Notably, his recent activity has been exclusively focused on selling, with three transactions in February 2026 totaling $111,913.77. These include sales of $24,327 on February 24, $50,850.15 on the same date, and $36,736.62 on February 18, 2026. Prior to this, Mark executed significant sales in December 2025 ($64,659.28), September 2025 ($357,700), and March 2025 ($495,300), often accompanied by smaller acquisitions through market purchases or exercises of derivative securities.
Mark’s trading pattern reveals a consistent reduction in his holdings of VCEL shares, with no recent purchases to offset the sales. The absence of buy transactions in 2026 underscores this trend, suggesting a strategic divestment rather than periodic rebalancing. While the filings do not disclose the rationale behind these transactions, the data highlights a sustained shift away from accumulating VCEL stock. This activity aligns with broader trends in insider trading, where executives may reduce their positions for personal financial planning or portfolio diversification. The focus on VCEL, a company specializing in advanced cell therapies, underscores Mark’s long-standing association with the firm, even as he reduces his equity stake.
AI-assisted summary